S. 4109: Stem Cell Therapeutic and Research Reauthorization Act of 2026

The Stem Cell Therapeutic and Research Reauthorization Act of 2026 aims to extend and update provisions related to stem cell research and therapy in the United States. Here are the key components of the bill:

Funding for Stem Cell Programs

The bill reauthorizes financial support for the C.W. Bill Young Cell Transplantation Program. Specifically:

• The funding level is set at $31,009,000 for the current fiscal year.
• For each fiscal year from 2027 through 2031, the funding will increase to $33,009,000.

Extensions for Cord Blood Inventory

The bill extends the timeline for maintaining an inventory of cord blood until 2031. This means that the program will continue to collect and manage cord blood units that can be used for transplantation and research purposes beyond the previously established end date of 2026.

Objective and Purpose

The overall goal of the legislation is to ensure the continuity of stem cell research and therapies that utilize stem cells, as well as to support the collection and availability of cord blood for medical use. This is seen as important for improving patient outcomes in treatments that require stem cell transplants, such as certain blood disorders and cancers.

Implications

By reauthorizing these programs and increasing funding, the bill seeks to enhance the capabilities of research institutions and hospitals involved in stem cell therapy and transplantation. This could lead to advancements in medical treatments that depend on these technologies and resources.

Relevant Companies

• BCEL - Bellicum Pharmaceuticals may see impacts through developments in stem cell therapies.
• FLML - Flexion Therapeutics could be influenced by advancements in stem cell treatments used for their therapeutic approaches.